AKT1 and melanoma: Ipatasertib showed dose-dependent inhibition of AKT signaling antitumor in vitro and in vivo in human tumor models with activated Akt signaling, representing a spectrum of cancer types, which includes prostate, breast, ovarian, colorectal, non-small cell lung, glioblastoma, and melanoma [22].